|Other Names||Cadherin-15, Cadherin-14, Muscle cadherin, M-cadherin, CDH15, CDH14, CDH3|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1435b was selected from the C-term region of human CDH15. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. M-cadherin is part of the myogenic program and may provide a trigger for terminal muscle differentiation.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed in the brain and cerebellum.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CDH15 is a member of the cadherin superfamily of genes, encoding calcium-dependent intercellular adhesion glycoproteins. Cadherins consist of an extracellular domain containing 5 cadherin domains, a transmembrane region, and a conserved cytoplasmic domain. Transcripts from this particular cadherin are expressed in myoblasts and upregulated in myotubule-forming cells. This protein is thought to be essential for the control of morphogenetic processes, specifically myogenesis, and may provide a trigger for terminal muscle cell differentiation.
Kang,J.S., Proc. Natl. Acad. Sci. U.S.A. 100 (7), 3989-3994 (2003)Hollnagel,A., Mol. Cell. Biol. 22 (13), 4760-4770 (2002)Meigs,T.E., Proc. Natl. Acad. Sci. U.S.A. 98 (2), 519-524 (2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.